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Abstract
Background: Systemic sclerosis (scleroderma; SSc) is an orphan disease with the highest case-specific mortality of
any connective-tissue disease. Excessive collagen deposit in affected tissues is a key for the disease’s pathogenesis
and comprises most of the clinical manifestations. Lidocaine seems to be an alternative treatment for scleroderma
considering that: a) the patient’s having excessive collagen deposits in tissues affected by scleroderma; b) the
patient’s demonstrating increased activity of the enzyme prolyl hydroxylase, an essential enzyme for the
biosynthesis of collagen; and c) lidocaine’s reducing the activity of prolyl hydroxylase. The aim of this study was to
evaluate the efficacy and safety of lidocaine in treating scleroderma.
Methods: A randomized double-blind clinical trial included 24 patients with scleroderma randomized to receive
lidocaine or placebo intravenously in three cycles of ten days each, with a one-month interval between them.
Outcomes: cutaneous (modified Rodnan skin score), oesophageal (manometry) and microvascular improvement
(nailfold capillaroscopy); improvement in subjective self-assessment and in quality of life (HAQ).
Results: There was no statistically significant difference between the groups for any outcome after the treatment
and after 6-months follow-up. Improvement in modified Rodnan skin score occurred in 66.7% and 50% of placebo
and lidocaine group, respectively (p = 0.408). Both groups showed an improvement in subjective self-assessment,
with no difference between them.
Conclusions: Despite the findings of a previous cohort study favouring the use of lidocaine, this study
demonstrated that lidocaine at this dosage and means of administration showed a lack of efficacy for treating
scleroderma despite the absence of significant adverse effects. However, further similar clinical trials are needed to
evaluate the efficacy of lidocaine when administered in different dosages and by other means.
Background
Systemic sclerosis (scleroderma; SSc) is an orphan dis-
ease with the highest case-specific mortality of any con-
nective-tissue disease [1]. It is a generalised disorder
affecting small arteries, microvessels and diffuse connec-
tive tissue and is characterised by fibrosis and vascular
obliteration in the skin, gastrointestinal tract, lungs,
heart and kidneys, in which hidebound skin is the most
distinctive clinical characteristic and organ degeneration
is the basis for prognosis [2]. Its aetiology is unknown,
however excessive collagen deposit in affected tissues is
a key for the disease’s pathogenesis and comprises most
of the clinical manifestations of this disease, determining
its development and prognosis; concurrently, numerous
treatment attempts target these collagen deposits during
various stages of the disease [3].
Treatment is difficult, and previous studies have often
failed to demonstrate improvements to the skin or other
organs using a variety of therapies, including immuno-
suppressive agents, putative antifibrotic drugs and highly
specific, targeted biological therapies [4].
A cohort study, published in 1977, demonstrated that
lidocaine appears to be an alternative treatment for
patients with scleroderma - associated with an improve-
ment in the cutaneous disorders and oesophageal manifes-
tations and with no adverse effects [5]. This experimental
cohort study included 15 patients with SSc and one
patient with localized scleroderma. Participants received
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500ml of glucose solution (5% concentration) during six
hours of infusion, for ten consecutive days, according to
the following doses: 400mg on the first day, 480mg on the
second, 560mg on the third, 640mg on the fourth, 720mg
on the fifth and 800mg on the last five days. This cycle
was repeated after 30, 60, 120 and 180 days and then every
six months [5]. The outcomes were assessed before the
treatment and after each cycle. According to the subjective
evaluations made by the investigator and the patient inde-
pendently, there was improvement in skin thickening in
75% of patients, in the oral cavity opening in 69% and in
dysphagia in 66% of them. There was no change in the
radiographic and electrocardiographic patterns and no
occurrence of moderate or severe adverse effects during
and after the infusions as well.
The rationale for this treatment presupposes three
conditions: a) the patient’s having excessive collagen
deposits in tissues affected by scleroderma [3]; b) the
patient’s demonstrating increased activity of the enzyme
prolyl hydroxylase, an essential enzyme for the biosynth-
esis of collagen, in the body’ tissues [6]; and c) lido-
caine’s reducing the activity of prolyl hydroxylase [7].
Since the publication of this study, this method of
intervention had been used by the Rheumatology
Department of the Federal University of Sao Paulo as an
alternative treatment for scleroderma patients with cuta-
neous and oesophageal manifestations.
Given the severity of the disease, its high mortality
rate and the absence of effective treatments for sclero-
derma, it is relevant to assess the effectiveness of new
therapeutic approaches. Therefore, the aim of this study
was to evaluate the efficacy and the safety of lidocaine
in treating scleroderma and thus increase the level of
evidence for this intervention available in medical
literature.
Methods
A double-blind randomized clinical trial conducted in
accordance with the Declaration of Helsinki and the
CONSORT Statement (Consolidated Standards of
Reporting Trials) [8], following approval by the Local
Ethics Committee and trial registered in the Clinical
Trials Database (NCT00740285).
Patients
Eligible for participation were those patients with diffuse
or limited SSc according to the American College of
Rheumatology (ACR) criteria [9]. Inclusion criteria: age
between 18 and 60 years old and time of onset of first
sign or symptom less than five years. Exclusion criteria:
SSc without cutaneous manifestations or caused by
external agent; mental illness; pregnancy; overlap with
other connective tissue disease; fibromyalgia; mandatory
use of beta-blockers or cimetidine; or previous use of
lidocaine, cyclophosphamide, d-penicillamine at any
point over the previous six months. The use of the fol-
lowing concurrent treatment was not allowed during the
study: methotrexate; azathioprine; chlorambucil; cyclos-
porine; interferon gamma; 5-fluorouracil; dimethyl sulf-
oxide; cyclofenil; n-acetylcysteine; para-aminobenzoate;
vitamin D3; isotretinoin; anti-thymocytes globulin;
cyclophosphamide; or d-penicillamine. Criteria for with-
drawal from the study: the mandatory use of one of the
aforementioned drugs during the trial.
Interventions
After a full informed consent, participants were rando-
mized in two groups: a) lidocaine 2% without vasocon-
strictor; b) placebo. The interventions was administered
intravenously for four hours, with 20mL administered
during the first five days and 30mL during the last five
days of treatment, in three cycles of ten days each, with
a one-month interval between them. The drug and pla-
cebo were diluted in 500mL of a 0.9% saline solution.
Randomization, Blinding and Allocation Concealment
Procedures
To ensure homogeneity between the groups, randomization
was matched and conducted by an independent researcher
who did not know the patients. The following variables
were used for pairing: patient’s age; type of involvement
(limited or diffuse); use of corticosteroids; and duration of
the disease since its first manifestation or symptom.
After the randomization, the bottles were identified by
the randomizer with the initials of the patient and they
were delivered to the nurse in charge of the administra-
tion. The two interventions had the same physical
appearance, colour and packaging. The patients, the
nurse who administered the medications and the
researchers who assessed the outcomes were blinded as
to the intervention received by each patient.
Outcomes
All outcomes were assessed before the intervention,
immediately following the final treatment and after the 6-
months follow-up period. The primary outcome was a
decrease in the modified Rodnan skin score (RSS-m) by at
least 30% immediately following three cycles of treatment.
This score evaluates cutaneous thickening in 17 body
areas, by clinical palpation, utilising a rating ranging from
0 (normal thickness) to 3 (extreme thickening) [10]. Con-
sistent with the clinical trial guidelines, to avoid intra-
observer variation and to minimise inter-observer varia-
tion, the score was applied twice to each patient blindly by
a single researcher with eight months of training [11].
The secondary outcomes were: a) an increase of at
least 30% in lower oesophageal sphincter pressure
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30% in the average amplitude of peristaltic contractions.
These outcomes were evaluated through an oesophageal
manometry (Medtronic/Gastrosystem DS-8800 Plus,
microcapillary infusion system- USA) carried out by a
single researcher with ten years of experience in the
method; b) a decrease of at least 30% in the number of
enlarged capillary loops and capillary dropout, as
assessed by nailfold capillaroscopy (stereomicroscope
Olympus - SZ40 under 10-20x magnification) conducted
by a single researcher, with five years of experience in
the method; c) an improvement of quality of life of at
least 30% on the Health Assessment Questionnaire
(HAQ), which was administered by a single researcher
after eight months of training; d) an improvement of
subjective global self-assessment as reported in a self-
administered questionnaire, which investigated patients’
opinion about oral cavity opening, skin pigmentation
and thickening, gastroesophageal complaints, arthralgia
and the biggest drawback in the study; e) adverse effects
as assessed through direct questioning of patients after
each cycle and via reports from the attending nurse
after spontaneous complaints during intervention.
Statistical Analysis
To calculate the sample size, we estimated a frequency
of 75% of the primary outcome in the lidocaine group
and a frequency of 20% in the placebo group, as
reported in the literature [5]. A type-1 error of 5%
(alpha) and type-2 error of 10% (beta) were assumed -
in other words, a significance level of 0.05 (p) and a
sample power of 90%. Therefore, the sample was com-
posed of 12 participants for each branch.
To assess the characteristics of data distribution
(Gaussian or otherwise), the Kolmogorov-Smirnov and
Shapiro-Wilk tests were applied.
The intra-class correlation coefficient was used to
evaluate the homogeneity of the values of SCR-m
obtained in both periods by the same investigator (intra-
observer variation) and the Pearson correlation test as
well. To allow this analysis, previously the Student T
test was applied to compare the mean scores obtained
between the two moments.
To compare the frequency of improvement in all out-
comes between the groups (improvement of at least
30%), we used the Chi-square test or Fisher’s exact test
if necessary.
To compare the average results obtained between
groups (named group effect) and also at the same time
between two time points (immediately after intervention
and after 6-months), the analysis of variance (ANOVA)
with repeated measures was applied, considering that
t h em e a s u r e so v e rt i m ew e r er e l a t e dt ot h es a m e
patient.
The Fisher’s exact test was used to compare the fre-
quency of adverse events between the two groups and
also the subjective issues of the self-assessment
questionnaire.
For all tests a significance level of 5% was considered
and an intention-to-treat analysis was performed.
Results
The study included 12 patients in each of the two
groups, which were similar in terms of the main vari-
ables (p > 0.05) due to paired randomization and there
were no withdrawals (Table 1).
Modified Rodnan Skin Score (RSS-m)
All the applied tests indicated a high agreement between
the two measures performed on each moment by the
same researcher (Table 2). The Pearson correlation test
between the two measures was 0,991 (before the treat-
ment), 0,994 (immediately after the treatment) and
0,997 (after the 6-months follow-up period). The intra-
class correlation coefficient was 0,991 (before the treat-
ment), 0,994 (immediately after the treatment) and
0,999 (after the 6-months follow-up period).
There was also no significant difference in the percen-
tage of improvement by at least 30% in the RSS-m
between the two groups (Table 3).
Oesophageal Involvement
Regarding lower oesophageal sphincter (LES) pressure,
there was no significant difference in the percentage of
Table 1 Baseline characteristics of patients
Placebo
group
(n = 12)
Lidocaine
group
(n = 12)
Gender, n (%)
Female 10 (83.4%) 10 (83.4%)
Male 2 (16.6%) 2 (16.6%)
Age, mean years ± SD 41.2 ± 11.1 40.8 ± 7.9
Type of involvement, n (%)
Limited 4 (33.3%) 3 (25%)
Diffuse 8 (66.6%) 9 (75%)
Duration of the disease since manifestation
of first symptoms, mean months (± SD
39.8 ± 15.9 41.5 ± 13.7
Use of corticosteroids, n (%) 8 (66.6%) 8 (66.6%)
Modified Rodnan skin score, mean ± SD 19.41 17.12
Capillary dropout, mean ± SD 1.8 ± 1.0 1.3 ± 1.1
Enlarged capillary loops, mean ± SD 4.04 2.90
Average amplitude of peristaltic contractions,
mean mmHg (± SD
48.2 ± 38.8 47.6 ± 49.2
Lower esophageal sphincter pressure (at
average airway pressure), mmHg mean ± SD
14.3 ± 6.9 13.6 ± 10.1
Health assessment questionnaire, mean ± SD 0.6 ± 0.4 0.8 ± 0.5
SD: standard deviation.
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least 30% in LES pressure between the two groups.
In relation to the average amplitude of the peristaltic
waves, there was also no significant difference in the
percentage of patients who showed an improvement
(increase) of at least 30% in amplitude between the two
groups. The values considered normal for this study’s
outcome ranged from 64 to 154mmHg (Table 3).
Microvascular Changes
Each patient’s fingernail beds were evaluated in order to
obtain an average frequency of enlarged loops and capil-
lary dropout. There was no significant difference in the
percentage of patients who showed an improvement
( r e d u c t i o n )b ya tl e a s t3 0 %i nt h en u m b e ro fe n l a r g e d
loops and amount of capillary dropout between the two
groups, when compared to the baseline data (Table 3).
Quality of Life and Subjective Self-Assessment
No statistically significant difference was found in the
percentage of patients who showed an improvement
(decrease) of at least 30% in their HAQ score when
compared to pre-intervention scores (p = 0.386).
The outcomes evaluated through the self-assessment
questionnaire are presented in Table 4.
Adverse Effects
Adverse effects were rare (four patients in the lidocaine
group and three in the placebo group), ephemeral and
mild: anxiety; palpitations (no change in heart rate dur-
ing the physical examination), itching; cramps;
hypoesthesia; nausea; and dizziness (Table 5). Most
effects occurred during treatment infusion, but there
was no need to interrupt or postpone infusion.
Comparing the outcomes measures after the interven-
t i o na n da t6 - m o n t h sf o l l o w - up (mid-term evaluation),
no statistically significant difference between lidocaine
and placebo groups were found and the values remained
unchanged during the study period in both groups.
Table 2 Intra-observer variation for modified Rodnan
skin score
n Mean Median SD Lower
Value
Higher
Value
P value*
RSS- m 1a 24 18,33 19 8,07 3 33 0,588
RSS-m 1b 24 18,21 17,5 8,17 3 33
RSS-m 2a 24 13,29 13,5 6,4 2 30 0,257
SCR-m 2b 24 13,46 13,5 6,33 2 30
RSS-m 3a 24 13,5 13,5 7,25 2 30 0,266
RSS-m 3b 24 13,38 13,5 7,29 2 30
* T Student test.
RSS-m 1a: modified Rodnan skin score - before treatment at moment 1; RSS-
m 1b: modified Rodnan skin score - before treatment at moment 2; RSS-m 2a:
modified Rodnan skin score - immediately after treatment at moment 1; RSS-
m 2b: modified Rodnan skin score - immediately after treatment at moment
2; RSS-m 3a: modified Rodnan skin score - after 6-months follow-up at
moment 1; RSS-m 3b: modified Rodnan skin score - after 6-months follow-up
at moment 2; SD: standard deviation.
Table 3 Percentage of improvement in the RSS-m,
oesophagus manometry and nailfold capillaroscopy
considering evaluation at baseline and immediately
following intervention
Placebo
group, n
%
Lidocaine
group, n
%
P-value
Improvement (decrease) in the
RSS-m by at least 30%
Yes 8 (66.7%) 6 (50%) 0.408*
No 4 (33.3%) 6 (50%)
Improvement (increase) in
lower oesophageal sphincter
pressure by at least 30%
Yes 3 (25%) 6 (50%) 0.206*
No 9 (75%) 6 (50%)
Improvement (increase) in the
amplitude of peristaltic waves
by at least 30%
Yes 2 (16.7%) 4 (33.3%) 0.346*
No 10 (82.3%) 8 (66.7%)
Improvement (reduction) in
the number of enlarged loops
by at least 30%
Yes 2 (16.7%) 4 (33.3%) 0.346*
No 10 (83.3%) 8 (66.7%)
Improvement (reduction) in
capillary avascular areas by at
least 30%
Yes 2 (16.7%) 2 (16.7%) 1.00*
No 10 (83.3%) 10 (83.3%)
* Fisher exact test.
Table 4 Subjective self-assessment
Placebo
group, n %
Lidocaine
group, n %
P-value
Improvement of oral cavity
opening
6 (50%) 7 (58.3%) 0.682*
Improvement of skin
pigmentation
8 (66.7%) 7 (58.3%) 0.673*
Improvement of skin
thickening
12 (100%) 12 (100%) 1.00
Improvement of
gastroesophageal
complaints
5 (41.7%) 8 (66.7%) 0.219*
Improvement of joint pain 5 (41.7%) 7 (58.3%) 0.414*
The biggest drawback to
trial participation
None 4 (33.3%) 4 (33.3%) 1.00
Oesophageal manometry 8 (66.7%) 8 (66.7%)
Would like to continue
receiving treatment
12 (100%) 12 (100%) 1.00
* Chi-square test.
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Despite the high morbidity and mortality associated with
SSc and the lack of effective treatment for most mani-
festations of this disease, few adequately designed stu-
dies have been or are being conducted to address this
shortcoming. A search of the Current Controlled Trials
Database found only 17 related intervention studies, a
similar search in Embase showed a mere 45 related
trials, while The Cochrane Library found 242 trials from
a database of more than 600,000 total trials (Table 6).
Foremost, the low prevalence of the disease and the delay
in finding patients who meet the classification criteria
make it difficult to include patients in studies of sclero-
derma. There was great difficulty in finding participants
whose first symptom had manifest in fewer than two years
prior to the study, two years being the timeframe recom-
mended by the ACR [12]. However, we attempted to follow
the recommendation for exclusion criteria exactly and to
ensure that patients with characteristics that could lead to
biased results were not included. We also followed the
recommendations contained in the CONSORT Statement
[8], and a stratified randomization was conducted in order
to avoid heterogeneity between groups for characteristics
that might influence results; all possible care was taken to
maintain allocation confidentiality, and we are confident
such was maintained; furthermore, an intention-to-treat
analysis was conducted. The unpredictable course of the
disease over time is undeniable regardless of the time of
onset and thus we tried to become the groups as similar as
possible to increase the internal validity without however
reducing the external validity of results.
The lidocaine dosage and its means of administration
were the same as those used in the previously published
cohort study [5]. The number of cycles (three) was cho-
sen by the researchers on account of the experience that
this intervention had earlier shown that patients with no
improvement in the first three cycles seemed to not
respond subsequent cycles.
The outcomes were selected in accordance with the
previously published cohort study, and the tools used
for assessing these outcomes (RSS-m, nailfold capillaro-
scopy, oesophageal manometry and the HAQ) had
already been validated [10,11,13-17]. Only one pre-
viously trained professional who had experience with
the tool was indicated to assess each outcome. Further-
more, with respect to the RSS-m, the same observer
twice assessed the same patient (in each assessment)
and achieved good correlation pursuant to the Pearson
test.
According to the Jadad scale, which assess the metho-
dological quality of randomized controlled trials, this
study achieved a score of 5, characterised by an ade-
quate and explicit process of randomization, appropriate
blinding and no losses [18]. Also, applying the risk of
bias table proposed by the Cochrane Collaboration, this
would be a low risk of bias clinical trial [19].
Regarding the results, which showed similar effects for
the intervention and placebo groups through objective
evaluation of outcomes, the authors do recognize the
importance of the publication of randomized clinical
trials with negative results, avoiding publication bias.
Also, it is important to highlight the following inter-
esting observation. In the subjective self-evaluation and
Table 5 Frequency of adverse effects
Group
Placebo Lidocaine P value
n%n%
Frequency of
adverse effects
No adverse effect 9 75,0% 6 50,0% 0,400 (F)
At least one effect 3 25,0% 6 50,0%
(F): Fisher exact test.
Table 6 Randomized clinical trials of scleroderma*
Database Search Strategy Results RCT
related*
Cochrane Library scleroderma OR (systemic sclerosis) in Title, Abstract or Keywords not (multiple sclerosis) in Title,
Abstract or Keywords in Cochrane Central Register of Controlled Trials (05/Sep/2010)
377 242
Embase scleroderma OR (systemic sclerosis) Limits: Clinical Trial, Randomized Controlled Trial, Clinical Trial,
Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial (05/Sep/2010)
423 42
Pubmed scleroderma OR (systemic sclerosis) Limits: Clinical Trial, Randomized Controlled Trial, Clinical Trial,
Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial (05/Sep/2010)
760 115
Lilacs esclerodermia [Palavras] or (esclerose sistemica) [Palavras] and ( “ENSAIO CLINICO” )o r“ENSAIO
CLINICO” or “ENSAIO CLINICO CONTROLADO” or “ENSAIO CLINICO CONTROLADO ALEATORIO” or
“ENSAIO CLINICO FASE III” or “ENSAIO CLINICO FASE IV” [Tipo de publicação] (05/Sep/2010)
30
Cilnical Trials Register
Database
scleroderma OR (systemic sclerosis) (05/Sep/2010) 140 104
Current Controlled
Trials Database
scleroderma OR (systemic sclerosis) in ISRCTN Register (International) (05/Sep/2010) 38 17
RCT: Randomized clinical trials; Lilacs: Latin American and Caribbean Health Sciences Literature (Literatura Latino-Americana e do Caribe em Ciências da Saúde); *
ECR really related with the theme - this was considered after the assessment of each abstract found and the full text, if necessary.
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reported improvement of skin thickening and, further,
willingness to continue receiving the same treatment.
Here we must stress the psychological side of the disease
and ask whether the fact of having received more medical
attention and more intensive care from health profes-
sionals might not have influenced patients’ response to
treatment. Intervention was conducted in a separate room
in which a number of other scleroderma patients were
receiving some type of treatment for other manifestations
of the disease (e.g., cyclophosphamide for pulmonary
involvement). Thus, treatment provided an opportunity to
meet people with the same disease and with the same skin
appearance, an aspect that elsewhere so often leads to stig-
matisation. Feeling safer and less different, patients notor-
iously created bonds with others in similar situations and
with the nurse in charge. We therefore believe that this
aspect should be considered in this discussion.
Finally, as expected, considering the discomfort
involved in administering treatment, patients reported
that the study’s biggest drawback was undergoing oeso-
phageal manometry on three occasions.
Despite methodological care, we must point out some
limitations in this study that should be avoided in future
studies: a) During the sample size calculation was
expected an improvement in primary outcome (RSS-m)
of 75% in the intervention group (as reported in the lit-
erature) [5] and 20% in the placebo group (expected dif-
f e r e n c eo f5 5 % ) .H o w e v e r ,t h er e s u l t ss h o w e das m a l l e r
difference (66.7% versus 50%, p = 0408), leading to a
important reduction in the power of the sample initially
calculated e used in this study; b) This trial included
patients with more than two years since the first mani-
festation of the disease, contrary to the suggestion of the
American ACR [12]; and c) the use of a fixed dosage of
lidocaine, not one adjusted to each patient’s weight.
Considering the findings of this clinical trial, our ser-
vice centre has suspended the use of lidocaine as an
alternative therapy for patients with cutaneous and
oesophageal involvement in SSc.
Conclusions
Despite the fact that the physiopathology, the research-
ers’ initial experience (level of evidence V) [19] and the
available cohort study (level of evidence IV) [20]
favoured the use of medication, this clinical trial (level
of evidence 1c) [20] has shown that lidocaine at this
dosage and this means of administration was not effec-
tive in the treatment of skin, oesophageal and microvas-
cular involvement in scleroderma or in improvement of
patients’ quality of life, despite the absence of significant
adverse effects.
However, we believe further clinical trials, keeping the
rigorous methodology, are needed to evaluate the
effectiveness of lidocaine when administered in different
dosages and by other means.
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